

Quanterix

Quanterix Names PBL Assay Science as a Preferred Partner in Assay Development and Testing Services

In response to growing customer demand, PBL will leverage Quanterix' Simoa technology to provide enhanced sensitivity for assay development across a broad range of therapeutic areas

Lexington, Mass. – June 15, 2015 — [Quanterix Corporation](#), a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced an alliance with [PBL Assay Science](#) (PBL), naming the Company as a Preferred Partner for assay research and development. Leveraging Simoa's sensitivity and revolutionary digital approach for assay development and research, PBL will have the ability to enter new markets and strengthen its current offerings.

As a leading provider of products, services, information, and know-how related to interferons, cytokines, antibodies, ELISAs, and assay solutions, PBL Assay Science is working hand in hand with industry, academic and government researchers to solve difficult assay development and protein quantification problems for its customers. Using Simoa's single molecule detection capabilities, PBL will be able to provide their customers with a completely automated experience, ensuring consistent results and the greatest sensitivity possible.

"PBL's alliance with Quanterix is a natural fit for our companies. Incorporating Simoa's ultrasensitive single molecule measurement into our pipeline of assay development and services capabilities allows us to enter new markets and significantly strengthen current offerings," said Dr. Thomas Lavoie, Chief Scientific Officer, PBL. "We have built a robust line of ELISA, protein, and antibody products, and have extensive experience in developing and executing high sensitivity biomarker assays. These capabilities are well complemented by Quanterix' Single Molecule Array technology to provide answers to problems in disease biology where basal levels of biomarker analytes have been extremely difficult to quantify. We anticipate our collaboration with Quanterix will bring unique content onto the platform and deliver high sensitivity assay development."

"We're excited to add PBL to our preferred partner program," said Kevin Hrusovsky, CEO and Executive Chairman at Quanterix. "By combining their deep-rooted expertise in solving difficult assay development and protein quantification problems with the service offerings available in our own Simoa HD-1 Accelerator Lab, we're confident that this partnership will accelerate assay development and lead to groundbreaking discoveries in diverse therapeutic areas of research."

To learn more about Simoa, please visit: www.quanterix.com.

About PBL

PBL Assay Science is a major provider of products, services, information, and know-how related to interferons, cytokines, antibodies, ELISAs, and assay solutions. The company employs state-of-the-art technology in conducting assay services and manufacturing world-class products for scientists around the globe each day. Learn more at <https://www.pblassaysci.com>.

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing

applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.

###

Contacts:

Nikki Festa & Caitlyn Keating

PAN Communications

617-502-4300

quanterix@pancomm.com